您当前的位置:
Etoposide.
Etoposide是用于治疗多种癌症的化疗药物。 Etoposide通过与拓扑异构酶II和DNA形成复合物来抑制DNA合成。
目录号: PC10253 纯度: ≥98%
CAS No. :33419-42-0
商品编号 规格 价格 会员价 是否有货 数量
PC10253-100mg 100mg ¥600.00 请登录
PC10253-10mM (in 1mL DMSO) 10mM (in 1mL DMSO) ¥660.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Etoposide.
中文别名
依托泊苷;足叶乙苷;表鬼臼毒吡喃葡萄糖苷;依托泊甙;足叶乙甙;鬼臼亚乙基苷;4'-去甲基表鬼臼毒素-beta-D-乙叉吡喃葡萄糖甙;依托泊甘;2,3,5,6-四氟-4-羟基苯甲醛;Etoposide 依托泊甘;依托泊甙,0;依托泊甙标准品(JP);依托泊甘(约含的乙醇);依托泊苷 EP标准品;依托泊苷 USP标准品;依托泊苷 标准品;依托泊苷分离度用混合物 USP标准品;依托泊苷系统适应性 EP标准品;4'-去甲表鬼臼9 -(4,6-O-亚乙基-β-e-吡喃葡萄糖苷)VP-16-213;9-[4,6-O-(R)-亚乙基-β-D-吡哺葡萄糖苷]-4'-去甲基表鬼臼毒素;鬼臼乙叉苷;依托泊苷、鬼臼亚乙基苷;依托泊苷对照品;4'-去甲基表鬼臼毒素 9-(4,6-O-亚乙基-β-D-吡喃葡萄糖苷)
英文名称
Etoposide
英文别名
Etoposide;TENIPOSIDE;4'-demethylepipodophyllotoxin-(4,6-o-(r)-ethylidene-beta-d-glucopyranoside);4-demethylepipodophyllotoxin-beta-d-ethylideneglucoside;ETOPOSIDE(RG);4‘-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside);4'-Demethylepipodophyllotoxin 9-(4,6-O-Ethylidene-β-D-glucopyranoside);Demethylepipodophyllotoxin-beta-D-ethylideneglucoside;VP16;VP-16;VP16213;VP-16-213;4′-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside)
Cas No.
33419-42-0
分子式
C29H32O13
分子量
588.56
包装储存

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

生物活性

Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy.

性状

Solid

IC50 & Target[1][2]

Topoisomerase II

 

体外研究(In Vitro)

Etoposide is capable of causing cytotoxicity on pancreatic β-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway in RIN-m5F cells.
Etoposide and Anti-Human VEGF significantly abolish P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells.
Etoposide phosphate (0-1μM; 72 hours) inhibits HCT116 FBXW, FBXW and p53 as a dose-dependent manner, exhibits IC50s of 0.945 μM; 0.375 μM; and 1.437 μM, respectively.
Etoposide (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7 cells.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: HCT116 FBXW, FBXW and p53 cells
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibits HCT116 FBXWp>, FBXW and p53 cell growth as a concentration manner.

Western Blot Analysis

Cell Line: HCT116 FBXW7 or FBXW7 cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.
体内研究(In Vivo)

Etoposide (50 μM) and Anti-Human VEGF-treated hypoxic cells injected intravenously into immunodeficient mice reveals a reduced capacity to induce lung colonies, which also appear with a longer latency period. Etoposide (10 mg/kg/day, i.v.) with NSC 109724 and NSC 241240, reduces the tumor volume in the hepatoblastoma cell injected NMRI nude mice.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

ClinicalTrial
结构分类
来源
参考文献
溶解度数据
体外研究: 

DMSO : ≥ 39 mg/mL (66.26 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6991 mL 8.4953 mL 16.9906 mL
5 mM 0.3398 mL 1.6991 mL 3.3981 mL
10 mM 0.1699 mL 0.8495 mL 1.6991 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.25 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.25 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 3.

    建议依照次序添加每种溶剂: 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

  • 4.

    建议依照次序添加每种溶剂: 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

  • 5.

    建议依照次序添加每种溶剂: 1% DMSO    99% saline

    Solubility: ≥ 0.5 mg/mL (0.85 mM); Clear solution

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2